Selected article for: "acute respiratory distress syndrome pneumonia and MERS cov"
Author: Jarrahi, Abbas; Ahluwalia, Meenakshi; Khodadadi, Hesam; da Silva Lopes Salles, Evila; Kolhe, Ravindra; Hess, David C.; Vale, Fernando; Kumar, Manish; Baban, Babak; Vaibhav, Kumar; Dhandapani, Krishnan M.
Title: Neurological consequences of COVID-19: what have we learned and where do we go from here?
  • Cord-id: mc8ddz39
  • Document date: 2020_9_30
    • ID: mc8ddz39
    Snippet: The coronavirus disease-19 (COVID-19) pandemic is an unprecedented worldwide health crisis. COVID-19 is caused by SARS-CoV-2, a highly infectious pathogen that is genetically similar to SARS-CoV. Similar to other recent coronavirus outbreaks, including SARS and MERS, SARS-CoV-2 infected patients typically present with fever, dry cough, fatigue, and lower respiratory system dysfunction, including high rates of pneumonia and acute respiratory distress syndrome (ARDS); however, a rapidly accumulati
    Document: The coronavirus disease-19 (COVID-19) pandemic is an unprecedented worldwide health crisis. COVID-19 is caused by SARS-CoV-2, a highly infectious pathogen that is genetically similar to SARS-CoV. Similar to other recent coronavirus outbreaks, including SARS and MERS, SARS-CoV-2 infected patients typically present with fever, dry cough, fatigue, and lower respiratory system dysfunction, including high rates of pneumonia and acute respiratory distress syndrome (ARDS); however, a rapidly accumulating set of clinical studies revealed atypical symptoms of COVID-19 that involve neurological signs, including headaches, anosmia, nausea, dysgeusia, damage to respiratory centers, and cerebral infarction. These unexpected findings may provide important clues regarding the pathological sequela of SARS-CoV-2 infection. Moreover, no efficacious therapies or vaccines are currently available, complicating the clinical management of COVID-19 patients and emphasizing the public health need for controlled, hypothesis-driven experimental studies to provide a framework for therapeutic development. In this mini-review, we summarize the current body of literature regarding the central nervous system (CNS) effects of SARS-CoV-2 and discuss several potential targets for therapeutic development to reduce neurological consequences in COVID-19 patients.

    Search related documents:
    Co phrase search for related documents
    • abdominal pain and acute coronary syndrome: 1
    • abdominal pain and acute phase: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • abdominal pain and acute respiratory failure: 1, 2, 3, 4, 5, 6
    • abdominal pain and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • abdominal pain and acute time: 1
    • abdominal pain and acute weakness: 1
    • acquire immunity and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4
    • activate neutrophil and acute ards respiratory distress syndrome: 1
    • activate neutrophil and acute sars cov respiratory syndrome coronavirus: 1
    • acute ards respiratory distress syndrome and adaptive immunity: 1, 2, 3, 4, 5, 6, 7
    • acute coronary syndrome and adaptive immunity: 1
    • acute phase and adaptive immunity: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory failure and adaptive immunity: 1, 2, 3, 4, 5
    • acute sars cov respiratory syndrome coronavirus and adaptive immunity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25